2026-06-14T03:47:12Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/116062025-04-08T07:26:47Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16988

00925njm 22002777a 4500 dc Vigon-Hernandez, Lorena author Luna, Alejandro author Galán Burgos, Miguel author Rodríguez-Mora, Sara author Fuertes, Daniel author Mateos, Elena author Piris-Villaespesa, Miguel author Bautista, Guiomar author San José, Esther author Rivera-Torres, José author Steegmann, Juan Luis author De Ory, Fernando de author Perez-Olmeda, Mayte author Alcamí, José author Planelles, Vicente author Lopez-Huertas, Maria Rosa author García-Gutiérrez, Valentín author Coiras, Mayte author 2020-12-25 BCR-ABL is an aberrant tyrosine kinase responsible for chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs) induce a potent antileukemic response mostly based on the inhibition of BCR-ABL, but they also increase the activity of Natural Killer (NK) and CD8+ T cells. After several years, patients may interrupt treatment due to sustained, deep molecular response. By unknown reasons, half of the patients relapse during treatment interruption, whereas others maintain a potent control of the residual leukemic cells for several years. In this study, several immunological parameters related to sustained antileukemic control were analyzed. According to our results, the features more related to poor antileukemic control were as follows: low levels of cytotoxic cells such as NK, (Natural Killer T) NKT and CD8±TCRγβ+ T cells; low expression of activating receptors on the surface of NK and NKT cells; impaired synthesis of proinflammatory cytokines or proteases from NK cells; and HLA-E*0103 homozygosis and KIR haplotype BX. A Random Forest algorithm predicted 90% of the accuracy for the classification of CML patients in groups of relapse or non-relapse according to these parameters. Consequently, these features may be useful as biomarkers predictive of CML relapse in patients that are candidates to initiate treatment discontinuation. J Clin Med . 2020 Dec 25;10(1):42. 10.3390/jcm10010042 2077-0383 Journal of clinical medicine 33375572 http://hdl.handle.net/20.500.12105/11606 Chronic myeloid leukemia Immunological response Treatment-free remission Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission.